{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:52:01Z","timestamp":1790484721931,"version":"4.1.0"},"reference-count":49,"publisher":"Japan Atherosclerosis Society","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAT","J Atheroscler Thromb"],"published-print":{"date-parts":[[2021,2,1]]},"DOI":"10.5551\/jat.55327","type":"journal-article","created":{"date-parts":[[2020,4,23]],"date-time":"2020-04-23T22:05:42Z","timestamp":1587679542000},"page":"103-123","source":"Crossref","is-referenced-by-count":37,"title":["Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE)"],"prefix":"10.5551","volume":"28","author":[{"given":"Shizuya","family":"Yamashita","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Department of Community Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Arai","sequence":"additional","affiliation":[{"name":"The National Center for Geriatrics and Gerontology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Bujo","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory and Experimental Research Medicine, Toho University, Sakura Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisaku","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tohru","family":"Ohama","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine"},{"name":"Department of Dental Anesthesiology, Osaka University Graduate School of Dentistry"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Ishibashi","sequence":"additional","affiliation":[{"name":"Ohara General Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Yanagi","sequence":"additional","affiliation":[{"name":"Kenporen Osaka Central Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuji","family":"Doi","sequence":"additional","affiliation":[{"name":"Saiseikai Senri Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Yamashiro","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Tanabe","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kita","sequence":"additional","affiliation":[{"name":"Kobe City College of Nursing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masunori","family":"Matsuzaki","sequence":"additional","affiliation":[{"name":"St. Hill Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Saito","sequence":"additional","affiliation":[{"name":"Chiba University Graduate School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Translational Research Center for Medical Innovation, Foundation for Biomedical Research and Innovation at Kobe"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Matsuzawa","sequence":"additional","affiliation":[{"name":"Sumitomo Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on Behalf of the PROSPECTIVE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3489","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Cholesterol Treatment Trialists' (CTT) Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A: Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet, 2015; 385: 1397-1405","DOI":"10.1016\/S0140-6736(14)61368-4"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tershakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators: Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med, 2015; 372: 2387-2397","DOI":"10.1056\/NEJMoa1410489"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators: Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017; 4; 376: 1713-1722","DOI":"10.1056\/NEJMoa1615664"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecorps G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators: Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med, 2018; 379: 2097-2107","DOI":"10.1056\/NEJMoa1801174"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Parthasarathy S, Young SG, Witztum JL, Pittman RC, Steinberg D: Probucol inhibits oxidative modification of low density lipoprotein. J Clin Invest, 1986; 77: 641-644","DOI":"10.1172\/JCI112349"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Fruebis J, Gonzalez V, Silvestre M, Palinski W: Effect of probucol treatment on gene expression of VCAM-1, MCP-1, and M-CSF in the aortic wall of LDL receptordeficient rabbits during early atherogenesis. Arterioscler Thromb Vasc Biol, 1997; 17: 1289-1302","DOI":"10.1161\/01.ATV.17.7.1289"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Barnhart JW, Sefranka JA, McIntosh DD: Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). Am J Clin Nutr, 1970; 23: 1229-1233","DOI":"10.1093\/ajcn\/23.9.1229"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Heel RC, Brogden RN, Speight TM, Avery GS: Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia. Drugs, 1978; 15: 409-428","DOI":"10.2165\/00003495-197815060-00001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Yamashita S, Matsuzawa Y: Where are we with probucol: a new life for an old drug? Atherosclerosis, 2009; 207: 16-23","DOI":"10.1016\/j.atherosclerosis.2009.04.002"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Yamashita S, Masuda D, Matsuzawa Y: Did we abandon probucol too soon? Curr Opin Lipidol, 2015; 26: 304-316","DOI":"10.1097\/MOL.0000000000000199"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol, 1986; 57: 29H-35H","DOI":"10.1016\/0002-9149(86)90434-0"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Naruszewicz M, Carew TE, Pittman RC, Witztum JL, Steinberg D: A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. J Lipid Res, 1984; 25: 1206-1213","DOI":"10.1016\/S0022-2275(20)34464-3"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Durrington PN, Miller JP: Double-blind, placebo-controlled, cross-over trial of probucol in heterozygous familial hypercholesterolaemia. Atherosclerosis, 1985; 55: 187-194","DOI":"10.1016\/0021-9150(85)90097-8"},{"key":"14","unstructured":"14) Baker SG, Joffe BI, Mendelsohn D, Seftel HC: Treatment of homozygous familial hypercholesterolaemia with probucol. S Afr Med J, 1982; 62: 7-11"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) Tawara K, Tomikawa M, Abiko Y: Mode of action of probucol in reducing serum cholesterol in mice. Jpn J Pharmacol, 1986; 40: 123-133","DOI":"10.1254\/jjp.40.123"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Cristol LS, Jialal I, Grundy SM: Effect of low-dose probucol therapy on LDL oxidation and the plasma lipoprotein profile in male volunteers. Atherosclerosis, 1992; 97: 11-20","DOI":"10.1016\/0021-9150(92)90046-J"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Franceschini G, Sirtori M, Vaccarino V, Gianfranceschi G, Rezzonico L, Chiesa G, Sirtori CR: Mechanisms of HDL reduction after probucol. Changes in HDL subfractions and increased reverse cholesteryl ester transfer. Arteriosclerosis, 1989; 9: 462-469","DOI":"10.1161\/01.ATV.9.4.462"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Hirano K, Ikegami C, Tsujii K, Zhang Z, Matsuura F, Nakagawa-Toyama Y, Koseki M, Masuda D, Maruyama T, Shimomura I, Ueda Y, Yamashita S: Probucol enhances the expression of human hepatic scavenger receptor class B type I, possibly through a species-specific mechanism. Arterioscler Thromb Vasc Biol, 2005; 25: 2422-2427","DOI":"10.1161\/01.ATV.0000185834.98941.3d"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Kita T, Nagano Y, Yokode M, Ishii K, Kume N, Ooshima A, Yoshida H, Kawai C: Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci U S A, 1987; 84: 5928-5931","DOI":"10.1073\/pnas.84.16.5928"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Br\u00e4sen JH, Koenig K, Bach H, Kontush A, Heinle H, Witting PK, Yl\u00e4-Herttuala S, Stocker R, Beisiegel U: Comparison of the effects of alpha-tocopherol, ubiquinone-10 and probucol at therapeutic doses on atherosclerosis in WHHL rabbits. Atherosclerosis, 2002; 163: 249-259","DOI":"10.1016\/S0021-9150(02)00023-0"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Walldius G, Erikson U, Olsson AG, Bergstrand L, H\u00e5dell K, Johansson J, Kaijser L, Lassvik C, M\u00f6lgaard J, Nilsson S, Sch\u00e4fer-Elinder L, Stenport G, Holme I: The effect of probucol on femoral atherosclerosis: the Probucol Quantitative Regression Swedish Trial (PQRST). Am J Cardiol, 1994; 74: 875-883","DOI":"10.1016\/0002-9149(94)90579-7"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Yamashita S, Bujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, Saito Y, Kita T, Matsuzawa Y: Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb, 2008; 15: 292-303","DOI":"10.5551\/jat.E610"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Yamashita S, Masuda D, Ohama T, Arai H, Bujo H, Kagimura T, Kita T, Matsuzaki M, Saito Y, Fukushima M, Matsuzawa Y; PROSPECTIVE Study Group: Rationale and design of the PROSPECTIVE trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease. J Atheroscler Thromb, 2016; 23: 746-756","DOI":"10.5551\/jat.32813"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Marks D, Thorogood M, Neil HA, Humphries SE: A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis, 2003; 168: 1-14","DOI":"10.1016\/S0021-9150(02)00330-1"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Yokoyama M, Origasa H, Matsuzaki M, Matsuzawa Y, Saito Y, Ishikawa Y, Oikawa S, Sasaki J, Hishida H, Itakura H, Kita T, Kitabatake A, Nakaya N, Sakata T, Shimada K, Shirato K; Japan EPA lipid intervention study (JELIS) Investigators: Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet, 2007; 369: 1090-1098","DOI":"10.1016\/S0140-6736(07)60527-3"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, Kashiwagi S, Hayashi J: Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol, 2002; 39: 610-616","DOI":"10.1016\/S0735-1097(01)01783-1"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Kang HJ, Kim MH, Sung J, Kim SH, Kim CH, Park JE, Ge J and Oh BH: On behalf of IMPACT on IMT investigators: Effect of probucol and\/or cilostazol on carotid intima media thickness in patients with coronary heart disease: a randomized, multicenter, multinational study. J Atheroscler Thromb, 2021; 28: 124-136","DOI":"10.5551\/jat.55616"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Sear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators: Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med, 2007; 357: 2109-2122","DOI":"10.1056\/NEJMoa0706628"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundl H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators: Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med, 2012; 367: 2089-2099","DOI":"10.1056\/NEJMoa1206797"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McErlean E, Wolski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahirkheli N, Mason D, Nissen SE; ACCELERATE Investigators: Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med, 2017; 376: 1933-1942","DOI":"10.1056\/NEJMoa1609581"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) HPS3\/TIMI55-REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ: Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med, 2017; 377: 1217-1227","DOI":"10.1056\/NEJMoa1706444"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Krishna R, Gheyas F, Liu Y, Hagen DR, Walker B, Chawla A, Cote J, Blaustein RO, Gutstein DE: Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther, 2017; 102: 832-840","DOI":"10.1002\/cpt.700"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Ishigami M, Yamashita S, Sakai N, Arai T, Hirano K, Hiraoka H, Kameda-Takemura K, Matsuzawa Y: Large and cholesteryl ester-rich high-density lipoproteins in cholesteryl ester transfer protein (CETP) deficiency can not protect macrophages from cholesterol accumulation induced by acetylated low-density lipoproteins. J Biochem, 1994; 116: 257-262","DOI":"10.1093\/oxfordjournals.jbchem.a124516"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Franceschini G, Chiesa G, Sirtori CR: Probucol increases cholesteryl ester transfer protein activity in hypercholesterolaemic patients. Eur J Clin Invest, 1991; 21: 384-388","DOI":"10.1111\/j.1365-2362.1991.tb01385.x"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Hong SC, Zhao SP, Wu ZH: Effect of probucol on HDL metabolism and class B type I scavenger receptor (SR-BI) expression in the liver of hypercholesterolemic rabbits. Int J Cardiol, 2007; 115: 29-35","DOI":"10.1016\/j.ijcard.2005.12.026"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Miida T, Seino U, Miyazaki O, Hanyu O, Hirayama S, Saito T, Ishikawa Y, Akamatsu S, Nakano T, Nakajima K, Okazaki M, Okada M: Probucol markedly reduces HDL phospholipids and elevated prebeta1-HDL without delayed conversion into alpha-migrating HDL: putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling. Atherosclerosis, 2008; 200: 329-335","DOI":"10.1016\/j.atherosclerosis.2007.12.031"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Yamashita S, Matsuzawa Y: Re-evaluation of cholesteryl ester transfer protein function in atherosclerosis based upon genetics and pharmacological manipulation. Curr Opin Lipidol, 2016; 27: 459-472","DOI":"10.1097\/MOL.0000000000000332"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Yamashita S, Ruscica M, Macchi C, Corsini A, Matsuzawa Y, Sirtori CR: Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists. Atherosclerosis, 2018; 278: 286-298","DOI":"10.1016\/j.atherosclerosis.2018.09.035"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Ishigami M, Yamashita S, Sakai N, Hirano K, Arai T, Maruyama T, Takami S, Koyama M, Kameda-Takemura K, Matsuzawa Y: High-density lipoproteins from probucol-treated patients have increased capacity to promote cholesterol efflux from mouse peritoneal macrophages loaded with acetylated low-density lipoproteins. Eur J Clin Invest, 1997; 27: 285-292","DOI":"10.1046\/j.1365-2362.1997.1040657.x"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Inagaki M, Nakagawa-Toyama Y, Nishida M, Nakatani K, Nakaoka H, Kawase M, Kawase R, Tsubakio-Yamamoto K, Masuda D, Ohama T, Matsuyama A, Ishigami M, Komuro I, Yamashita S: Effect of probucol on antioxidant properties of HDL in patients with heterozygous familial hypercholesterolemia. J Atheroscler Thromb, 2012; 19: 643-656","DOI":"10.5551\/jat.12807"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Zucoloto AZ, Manchope MF, Staurengo-Ferrari L, Pinho-Ribeiro FA, Zarpelon AC, Saraiva ALL, Cec\u00edlio NT, Alves-Filho JC, Cunha TM, Menezes GB, Cunha FQ, Casagrande R, Verri WA Jr: Probucol attenuates lipopolysaccharide-induced leukocyte recruitment and inflammatory hyperalgesia: effect on NF-\u03baB activation and cytokine production. Eur J Pharmacol, 2017; 809: 52-63","DOI":"10.1016\/j.ejphar.2017.05.016"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Li T, Chen W, An F, Tian H, Zhang J, Peng J, Zhang Y, Guo Y: Probucol attenuates inflammation and increases stability of vulnerable atherosclerotic plaques in rabbits. Tohoku J Exp Med, 2011; 225: 23-34","DOI":"10.1620\/tjem.225.23"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Yoshikawa T, Mitani K, Kotosai K, Nozako M, Miyakoda G, Yabuuchi Y: Antiatherogenic effects of cilostazol and probucol alone, and in combination in low density lipoprotein receptor-deficient mice fed with a high fat diet. Horm Metab Res, 2008; 40: 473-478","DOI":"10.1055\/s-2008-1065348"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Li S, Liang J, Niimi M, Bilal Waqar A, Kang D, Koike T, Wang Y, Shiomi M, Fan J: Probucol suppresses macrophage infiltration and MMP expression in atherosclerotic plaques of WHHL rabbits. J Atheroscler Thromb, 2014; 21: 648-658","DOI":"10.5551\/jat.21600"},{"key":"45","unstructured":"46) Kim BJ, Lee EJ, Kwon SU, Park JH, Kim YJ, Hong KS, Wong LKS, Yu S, Hwang YH, Lee JS, Lee J, Rha JH, Heo SH, Ahn SH, Seo WK, Park JM, Lee JH, Kwon JH, Sohn SI, Jung JM, Navarro JC, Kang DW; PICASSO investigators: Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurol, 2018; 17: 509-518"},{"key":"46","doi-asserted-by":"crossref","unstructured":"47) Wu BJ, Di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, Ward MR, Stocker R: Probucol [4,4'-[(1-methylethylidene)bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficient mice. J Pharmacol Exp Ther, 2007; 321: 477-484","DOI":"10.1124\/jpet.106.118612"},{"key":"47","doi-asserted-by":"crossref","unstructured":"48) Matsuzawa Y, Yamashita S, Funahashi T, Yamamoto A, Tarui S: Selective reduction of cholesterol in HDL2 fraction by probucol in familial hypercholesterolemia and hyperHDL2 cholesterolemia with abnormal cholesteryl ester transfer. Am J Cardiol, 1988; 62: 66B-72B","DOI":"10.1016\/S0002-9149(88)80055-9"},{"key":"48","doi-asserted-by":"crossref","unstructured":"49) Yamamoto A, Takaichi S, Hara H, Nishikawa O, Yokoyama S, Yamamura T, Yamaguchi T: Probucol prevents lipid storage in macrophages. Atherosclerosis, 1986; 62: 209-217","DOI":"10.1016\/0021-9150(86)90095-X"},{"key":"49","doi-asserted-by":"crossref","unstructured":"50) Yamamoto A, Matsuzawa Y, Yokoyama S, Funahashi T, Yamamura T, Kishino B: Effects of probucol on xanthomata regression in familial hypercholesterolemia. Am J Cardiol, 1986; 57: 29H-35H","DOI":"10.1016\/0002-9149(86)90434-0"}],"container-title":["Journal of Atherosclerosis and Thrombosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/2\/28_55327\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,6]],"date-time":"2021-02-06T04:00:34Z","timestamp":1612584034000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jat\/28\/2\/28_55327\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":49,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.5551\/jat.55327","relation":{},"ISSN":["1340-3478","1880-3873"],"issn-type":[{"value":"1340-3478","type":"print"},{"value":"1880-3873","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]}}}